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INTRODUCTION 
Biomarker is a characteristic, that is measured objectively and evaluated as an 
indicator of normal biological or pathological process and also as a pharmacologic response 
to therapeutic intervention. These biomarkers are useful for screening, risk assessment before 
diagnosis and also for selection of therapy, monitoring the therapy and recurrent diseases.1 
Resistin is one of the newly recognised adipokine with all qualities of an ideal 
biomarker.1 It was named after its characteristic function of resisting insulin. Resistin is a 
12.5kDa cysteine which is a secretory protein consisting of 108 amino acids mainly involving 
in inflammation and found in FIZZ 3 (Found in inflammatory zone -3).2 It is expressed in 
very low level in adipocytes and higher level in circulating monocytes, macrophages, 
lymphocytes and mononuclear leukocytes.3 Some of the inflammatory conditions where 
resistin levels are found to be increased include rheumatoid arthritis, diabetes mellitus, 
retinopathy, chronic kidney diseases, atherosclerosis, coronary artery diseases and 
periodontitis.1 
Chronic periodontitis is an infectious disease resulting in inflammation within the 
supporting tissues of the teeth, progressive attachment loss and bone loss.4 
This chronic inflammatory response in periodontitis is caused by periodontopathogens 
present in hard and soft deposits on the tooth surface. These microorganisms and their 
products (protease, collagenase, hyaluronidase, chondroitin sulfatase, endotoxins) 
spontaneously trigger a cascade of immunomodulatory reaction in the host, hoping to ward 
off the progressing infection. But what happens is, along with these cascade of events various 
pro inflammatory cytokines and large quantities of destructive enzymes such as matrix 
metalloproteinase and inflammatory mediators are produced resulting in more extracellular 
degradation, osteoclast activation and differentiation, leading to further collagen and bone 
Introduction 
 
2 
 
destruction ultimately ending up in more tissue destruction. These inflammatory mediators 
produced as a result of host immunomodulatory response in periodontitis serve as a 
biomarker for disease activity.1,5  
Chronic periodontitis is characterised by inflammation of periodontium with the 
infiltration of various inflammatory cells into the periodontal tissues. These inflammatory 
cells are the major source for resistin. Inturn, resistin also activates NF-kB dependant 
cytokine release and adhesion molecule expression. Lipopolysaccharide from 
periodontopathogens induce resistin gene found in macrophage through a cascade involving 
the production of proinflammatory cytokines.1 
As periodontitis is a sixth complication of diabetes, a bidirectional relationship has 
been established between diabetes and periodontitis, in which one has influence on the other. 
In periodontitis, with chronic subclinical inflammation, the insulin sensitivity is decreased 
with increase in resistin level. This increased resistin level also induces insulin resistance by 
influencing GLUT (Glucose Transporters) and increasing the risk for type 2 diabetes 
mellitus. Thus resistin could be one of the ideal biomarkers which provides link among 
Resistin – Periodontitis - Diabetes mellitus triad.1 
These proteins are detected in serum, plasma and other body fluids including GCF. 
GCF is considered to be an important diagnostic material containing host cell products 
(cytokines, antibody, enzymes), products of tissues destruction, plasma-derived molecules 
and sub gingival microbial products. In inflammatory conditions, there will be an increase in 
GCF flow as it is an inflammatory exudate. Hence determination of GCF derived biomarker 
combined with clinical measurements provide a sensitive measure for identification of 
periodontal disease progression and treatment outcomes.4 
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After non-surgical periodontal therapy (scaling and root planing) the periodontal 
conditions heal sufficiently with decreased clinical signs of inflammation with decreased 
levels of resistin. This decreased levels of resistin after non surgical periodontal therapy 
decreases the insulin resistance ultimately increasing the insulin sensititvity. Thereby it 
reduces the blood glucose level in patients with diabetes mellitus. Very few studies have 
documented the presence of GCF resistin in chronic periodontitis, type 2 diabetes mellitus 
and also its level after intervention. Hence the aim of this study is to detect the levels of 
resistin in GCF of patients with chronic periodontitis and in patients with chronic 
periodontitis and type 2 diabetes mellitus and also their levels after non-surgical periodontal 
therapy. 
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AIM: 
          To evaluate the levels of resistin in gingival crevicular fluid (GCF) before and after non 
surgical periodontal therapy in systemically healthy chronic periodontitis patients and in 
chronic periodontitis patients with type 2 diabetes mellitus. 
 
OBJECTIVES: 
1. To evaluate the clinical parameters and levels of resistin in gingival crevicular fluid of 
systemically healthy chronic periodontitis patients and in chronic periodontitis 
patients with type 2 diabetes mellitus before non surgical periodontal therapy. 
2. To evaluate the clinical parameters and levels of resistin in gingival crevicular fluid of 
systemically healthy chronic periodontitis patients and in chronic periodontitis 
patients with type 2 diabetes mellitus at 3 months following  non surgical periodontal 
therapy. 
3. To compare the levels of resistin in gingival crevicular fluid of chronic periodontitis 
patients with and without type 2 diabetes mellitus before non surgical periodontal 
therapy. 
4. To compare the clinical parameters and levels of resistin in gingival crevicular fluid 
of chronic periodontitis patients with and without type 2 diabetes mellitus at 3 months 
following non surgical periodontal therapy. 
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Chronic periodontitis is an infectious disease resulting in inflammation within the 
supporting tissues of the teeth, progressive attachment loss, and bone loss. Chronic periodontitis is 
most common form of periodontitis, seen in adults, but can also occur in children and adolescents in 
response to chronic accumulation of plaque and calculus.4 
 Microbial plaque and calculus that gets accumulated on the tooth surface that is in close 
proximity to the gingiva is considered to be the prime etiological factor for the inflammation of 
periodontal tissues.6 On the other hand, various systemic and environmental factors that affect the 
normal host-bacterial interaction can also accelerate the progression of periodontal diseases. It is 
generally a slowly progressive disease characterised by the presence of inflammation, pocket 
formation, attachment loss, and bone loss resulting from the direct, site-specific effects of 
subgingival plaque accumulation. 
PATHOGENESIS OF PERIODONTAL DISEASE: 
The primary etiologic agent for periodontal disease are periodontal pathogens. The 
periodontal microorganisms that have the ability to colonise, evade host defence mechanism, and 
ability to produce virulence factors are capable of causing periodontal disease. For decades, the 
initiation and progression of periodontitis has been considered to be caused by the presence of  
specific bacteria or groups of bacteria harbouring the subgingival plaque biofilm.7 
 In the current paradigm of periodontal disease, periodontal pathogens are necessary for the 
initiation of periodontal disease, however the extent and severity of periodontal tissue destruction 
are mainly dependent on the complex host-microbial interaction.4 
Periodontal disease is characterized by a complex interplay between the subgingival biofilm 
and the immune mediated inflammatory events occurring in the host tissue in response to bacterial 
challenge.8In periodontitis, the primary etiological agent is specific, mainly gram negative anaerobic or 
facultative bacteria harbouring the subgingival biofilm. The majority of periodontal tissue destruction 
results from exaggerated host response to these microorganisms and their products.7The host immune 
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system gets activated in response to pathogens and produces various pro inflammatory cytokines in 
order to ward off the infection. These inflammatory mediators are also used as a biomarkers for the 
periodontal disease. Biomarkers span a broad spectrum of human health care which helps in 
understanding human biology, diagnosis and risk assessments of particular disease. The biomarker is 
either produced by a diseased organ or by the body in response to a disease.1 Periodontitis is one such 
disease with various biomarkers including the newly discovered Resistin. 
RESISTIN: 
The novel protein, Resistin is a putative adipocyte derived signalling polypeptide which belongs 
to the group of adipokines. It is a 12.5kDa cysteine rich secretory protein consisting of 108 amino acids 
with important regulatory roles in various biological process.5 
DISCOVERY: 
Resistin was first described in 2001. It was discovered during the research on genes which are 
responsible for adipocyte differentiation.9It was also found that resistin was down regulated in mature 
adipocytes. The protein was named as Resistin after its proposed function of resisting insulin. It was 
identified originally in three different conditions. Initially it was observed in obesity and insulin 
resistance. Later,it was found that this protein was also involved in inflammation.10It is upregulated in 
obesity, insulin resistance and inflammation and down regulated by immunoneutralization which 
include insulin sensitivity. 
TISSUE DISTRIBUTION AND VARIOUS CONDITIONS: 
Tissue distribution of Resistin is seen in hypothalamus, pituitary, adrenal glands, pancreas, 
gastrointestinal tract, myocytes, spleen, white blood cells and plasma. It is also highly expressed in 
immune cells like monocytes, macrophages, neutrophils, lymphocytes and various body fluids in 
humans. It can also be detected in various inflammatory conditions like rheumatoid arthritis, diabetic 
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retinopathy, chronic kidney diseases, atherosclerosis, coronary heart disease and periodontitis. It is also 
known as FIZZ 3 (found in inflammatory -3) or ADSF (Adipocyte specific secretory factor).1,5,9 
RESISTIN LIKE MOLECULES (RELM): 
The resistin which is adipokine, is a cysteine rich protein. There are also other resistin like 
molecules (RELM). It includes RELM - α /FIZZ 1, RELM - β  /FIZZ 2, FIZZ 3 and RELM -γ/ FIZZ 
4.1,11 
FIZZ 1/RELM- α: It is the first isolated protein in FIZZ family. It is found on chromosome 11 
and located at II-q 21. It is expressed in white adipose tissue of the heart, lungs and tongue. It is present 
in the inflammatory zone of allergic pulmonary inflammation and is mostly found in bronchoalveolar 
fluid. 
FIZZ 2/RELM-β: It is found in proliferating epithelium of crypt and can be detected in high 
levels in stool of humans.  
FIZZ 3: Resistin belongs to the family of FIZZ. Cysteine is the most common amino acid in 
resistin which comprises approximately 12% of its amino acid sequence. It is mainly involved in 
inflammation and found in adipocytes and various immune cells. 
 FIZZ 4/RELM-γ: It is identified in hematopoietic tissues and in nasal respiratory epithelium. 
STRUCTURE: 
The resistin gene called as Retn is encoded with 108 amino acid polypeptide in humans and 114 
aminoacid  polypeptide in rats. It is secreted as disulfide – linked homodimer structure (Figure 
1A,B,C). This disulphide bond has to be cleaved to intiate the bioactivity. X-ray crystallographic 
studies showed complex hexameric structure. It is present in two distinct assembly states.9 
1.A high molecular mass hexamer which is more predominant. 
Review of literature 
 
8 
 
2. A low molecular mass complex which is more bio active.9 
 
                                                  
 
                                             
                                                       
 
 
 
 
FIGURE A: Monomeric structure 
of resistin 
FIGURE B: Hexameric form comprising 
of two disulphide-linked trimers 
FIGURE C: Interchain disulphide linkages 
present in the hexameric form of resistin 
FIGURE 1:Structure of resistin 
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FUNCTIONS OF RESISTIN IN INFLAMMATION: 
 Resistin induces the expression of pro inflammatory cytokines, cellular adhesion 
molecules, chemokines and matrix metalloproteinase in PBMCs, endothelial cells and adipocytes. 
 It inhibits chemotaxis and decreases the oxidative burst of human polymorphonuclear 
leucocytes.  
 It induces osteoclast differentiation by the stimulation of nuclear factor – kB 
transcriptional activity.11 
 
 
 
FIGURE 2: Amino acid sequence identities of rodent, porcine and bovine resistin, other 
RELM family members and the recently identified human alternatively spliced variant of 
resistin, h resistin 
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RESISTIN IN NEUTROPHILS: 
Periodontopathogens present in dental plaque, biofilm and food debris gets accumulated on the 
tooth surface. These microorganisms and its products, endotoxins initiate a cascade of host immuno 
modulatory responses. This immune response of the host against pathogenic microorganisms attempts 
to ward off the infections. During this cascade various pro inflammatory cytokines are produced. The 
imbalance between these two cytokines results in over production of pro inflammatory cytokines and 
large quantities of destructive enzymes such as MMPs and inflammatory mediators. This leads to 
extracellular degradation, osteoclast activation and differentiation leading to further collagen and bone 
destruction.13 
The important and major source for resistin is mononuclear leucocytes (neutrophils). The 
resistin is present in azurophil granules, specific granules and also on the cell membrane (membrane 
attached resistin) of neutrophils. The release of granular content from neutrophil is one of the major 
component of innate immune response. Neutrophils are one of the major fraction of leucocytes present 
in circulation and also at the site of inflammation. These neutrophils migrate to the site of inflammation 
by transendothelial migration in response to pathogens. This extravasation of neutrophils into inflamed 
tissue takes place by various chemoattractants.13 
RELEASE OF RESISTIN FROM IMMUNE CELLS: 
The resistin is upregulated and released from neutrophils by various pro inflammatory stimuli 
like TNF α, peptidoglycans, bacterial endotoxins. One of the major activator of neutrophil are these 
small formyl peptide derivates (FMLF) which is a chemo attractant mediator. These FMLF binds to 
FPR (formyl peptide receptor) and triggers the intra cellular activation mediated by G-Protein. This 
intracellular activation results in phosphorylation of intracellular kinases like phosphatidylinositol -3-
kinase, protein C kinase, mytogen – activated protein kinases and further leads to release of granular 
content. The activation of neutrophil by FPR induces extracellular release of resistin also.13 
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As chronic periodontitis is a low grade infection, it is characterised by infiltration of 
inflammatory cells into the periodontal tissues and it acts as a source for resistin production. Inturn 
resistin also activates NF-kB which releases various cytokines and adhesion molecule. 
Lipopolysaccharides produced by periodontal pathogens also induce resistin gene in macrophage via 
cascade involving the production of proinflammatory cytokines.    
 
 
       
 
RESISTIN-PERIODONTITIS-DIABETES MELLITUS- A TRIAD RELATIONSHIP: 
Periodontitis is considered to be the sixth complication of diabetes and a two way relationship 
has been established between diabetes and periodontitis. In periodontitis with chronic subclinical 
inflammation, the insulin sensitivity is decreased with increase in resistin level. Resistin plays an 
important role in insulin resistance, thus increasing the risk for type 2 diabetes mellitus. The insulin 
resistance is mediated by the action of resistin on the expression and localisation of GLUT (Glucose 
FIGURE 3: The relationship between periodontitis and adipokines 
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transmitter). It was found that chronic exposure to resistin adversely affects the entry of glucose into 
cells and thus counteracting the effect of insulin. Over expression of receptor tyrosine kinase – like 
orphan receptor (ROR 1) induces the expression of GLUT 1 and GLUT 4 in pre adipocytes, in which 
this action can be reversed by resistin. The interaction of the resistin and extracellular ROR 1 receptor 
results in ROR 1 phosphorylation and regulates the suppression of cytokine signalling, GLUT 1 and 
GLUT 4 expression.  ROR 1 plays an important role in adipogenesis and glucose homeostasis.1The 
amount and severity of periodontal tissue breakdown is influenced by T2DM.14 
GINGIVAL CREVICULAR FLUID: 
These proteins are detected in serum, plasma and other body fluids including GCF.GCF is 
considered to be an important diagnostic aid containing host cell products (cytokines, antibody, 
enzymes), products of tissues destruction, plasma-derived molecules and sub gingival microbial 
products. Gingival crevicular fluid is a transudate in healthy gingival crevice and an exudate in the 
inflammatory conditions mainly in periodontitis. It contains saccharides, electrolytes, cellular 
components, decayed products of periodontal tissue, bacteria and their products, various proteins 
including serum proteins, immunoglobulins, enzymes, periodontal tissue derived proteins and 
inflammation derived proteins, cytokines and bacterial proteins. Resistin is one of the proteins present 
in GCF. The increased levels of interleukin 1β, interleukin 6, TNF α which are pro inflammatory 
cytokines, are present in GCF of periodontitis patients. Hence determination of GCF derived biomarker 
combined with clinical measurements provide a sensitive measure for identification of periodontal 
disease progression.4,15 
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REVIEW OF LITERATURE 
Hasegawa et al.(2005)16 correlated the relationship between serum resistin levels in type 2 
diabetes mellitus patients and the patients with adiposity. About 111 type 2 diabetes patients and 98 
non-diabetic patients were included in this study. Blood samples were collected from all patients 
with overnight fast. Serum resistin level was determined by ELISA. The results showed significant 
increase in serum resistin level in type 2 diabetes mellitus patients when compared with non-
diabetic patients. From this study it was concluded that presence of diabetes mellitus and High 
density lipid (HDL) cholesterol were significant predictors of serum resistin levels. 
Bo S et al. (2005)17 evaluated the association between serum resistin levels, insulin 
resistance and marker of inflammation (C reactive protein). A total of 300 randomly selected 
patients with normal BMI were included. From all the patients venous blood was collected after an 
overnight fast. Glucose level, HDL cholesterol, uric acid, triglyceride, insulin, nitroglycerine and 
resistin were evaluated. Serum resistin level was evaluated by ELISA. The results showed that 
resistin, CRP level were significant in over weight patients. Resistin level was associated with CRP 
levels in all patients. From this study it was concluded that serum resistin was directly correlated 
with CRP and it is secreted in response to chronic low grade inflammation. 
Furugen R et al. (2008)18 conducted a study to clarify the relationship between serum 
adipokine level in patients with and without periodontitis. About 158 elderly  Japanese people with 
and without periodontitis  were included in the study. The clinical parameters includes probing 
pocket depth of ≥6mm in atleast one teeth for periodontitis and ≤6mm for control group. Bleeding 
on probing in ≥10% sites for periodontis patients and <10% for control group.BMI and FBS were 
analysed. Blood sample s were collected and stored at -80ºC.The levels of adiponectin, resistin, 
TNF α and IL-6 were examined using ELISA. Results showed higher levels of resistin in 
periodontitis patients than in control patients. No significant difference were observed in 
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adiponectin, IL-6 and TNF α levels between subjects with and without periodontitis. Serum 
adiponectin tended to decrease in patients with periodontitis but not significantly. 
Saito et al. (2008)19 conducted a study to correlate the relationship between serum levels of 
adipokine in periodontally healthy and chronic periodontitis patients. A total of 76 patients were 
included in the study with 2 groups. Group 1 consists of 34 patients with moderate to severe 
periodontitis and Group 2 consists of 42 healthy subjects. Periodontitis patients were categorized by 
probing depth ≥6mm in atleast 1 teeth and clinical attachment level in atleast 3 teeth with≥4mm.The 
subjects with healthy gingiva should have probing depth <3mm and no more than 2 teeth that bleed 
while probing. Fasted blood samples were collected and stored in freezer. Resistin, adiponectin, 
TNF α and IL-6 were analysed using ELISA. Statistical analysis was done. The results showed  
higher levels of adipokines and resistin in periodontitis patients than with healthy patients. 
Adiponectin levels were reduced in periodontitis patients but they were not statistically significant. 
From this study it was concluded that serum resistin level is associated with periodontitis and it may 
also have triangular relationship between obesity, type 2 diabetes mellitus and periodontal disease. 
Gharibeh et al. (2010)20 evaluated the insulin resistance markers in type 2 diabetes Mellitus 
patients, obesity and plasma resistin levels. Study includes 140 diabetic patients and 125 non-
diabetic patients. BMI was calculated. Blood were obtained in morning for all the patients after 
overnight fast. Human resistant in plasma was measured by ELISA. Results showed higher levels of 
resistin in diabetic patients than non-diabetic individuals. The patients who were > 60 years of age 
showed significant resistin levels than the patients who were below 40 years of age. It was 
concluded that resistin was involved in increased adiposity, insulin resistance and type 2 diabetes 
mellitus. 
Devanoorkar et al. (2012)21 conducted a study to determine the serum resistin level in 
periodontal health and disease patient and also evaluated the resistin level after non surgical 
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periodontal therapy. A total of 40 patients with two groups were included. Group I includes 20 
healthy patients with probing depth ≤ 3mm , clinical attachment level ≤ 1mm, Full mouth bleeding 
score less than 1. Group II- included 20 chronic periodontitis with 5mm pocket depth, clinical 
attachment level ≥2mm in at least four teeth with radiographic evidence of bone loss. Other 
parameters like gingival index, bleeding index, BMI were evaluated. About 2ml of blood samples 
were collected and centrifuged following this non surgical periodontal therapy. Blood samples were 
collected from group II patients two weeks after therapy. After analysis using ELISA, results 
showed higher serum levels in chronic periodontitis patients when compared to healthy patients. 
This study concluded that serum resistin levels does not show any difference between group I and 
group II and also decrease in serum resistin level following non surgical periodontal therapy. 
Hiroshima et al. (2012)12  evaluated the GCF resistin level in patients with and without 
periodontitis and Type II Diabetes mellitus and  also investigated the release of resistin from 
neutrophils after induction by Porphyromonas gingivalis lipopolysaccharides. The study includes 63 
patients and were divided into 3 groups. It consist of 24 chronic periodontitis patients, 18 Diabetes 
mellitus related periodontitis patients, 21 healthy patients. Periodontitis was defined by the probing 
depth of ≥4mm and for Diabetes patients HbA1c >5.8%. GCF was collected using paper strips and 
measured using Periotron 8000.The assay was done by western blotting and ELISA. Invitro analysis 
was done for neutrophils. Blood samples were collected from 6 healthy volunteers and the 
neutrophils were separated from the whole blood and seeded in culture dishes. The incubation is 
done with and without P-LPS. After culture, cells and medium were separately collected, 
centrifuged and used for analysis by ELISA. The results showed higher levels of resistin in 
periodontitis and Diabetes mellitus patients. P-LPS also increases resistin release from neutrophils 
which was also decreased in the presence of polymerisation inhibitors. From this study it was 
concluded that GCF resistin level were increased in periodontitis patients and is related to P-LPS 
induced release from neutrophils. 
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Kido et al. (2012)15  analysed the protein components in gingival crevicular fluid of healthy  
and periodontitis patients using mass spectrometry. This study includes 8 periodontitis patients with 
≥ 6mm and 1 periodontally healthy patient with ≤ 2mm.About 10µl of GCF was collected using 
paper strips and gel digestion was done. The samples were electrophorectically separated and 
analysed by nano liquid chromatography and mass spectrometery. The peptides detected were 
confirmed by western blotting. Results showed that 104 proteins were detected in both healthy and 
periodontitis patients. One among them is resistin. From this study it was concluded that multiple 
protein components were detected in gingival cervicular fluid and resistin was one among them. 
Patel et al. (2013)22 determined the levels of resistin in serum and gingival crevicular fluid 
and compared its level in patients with and without periodontitis and type 2 diabetes mellitus 
patients and correlated it with single nucleotide polymorphism at -420. The study includes a total of 
96 patients and were divided into four groups.Group1 includes 24 healthy patient, Group 2 includes 
24 periodontitis patients with uncontrolled diabetes,Group3 includes24 periodontitis patient with 
controlled diabetics and Group4 includes 24 chronic periodontitis patients without diabetes mellitus. 
The categorisation of groups was done based on the clinical parameters-Gingival index, clinical 
attachment level, probing pocket depth, haemoglobin A1c.GCF was collected on the next day after 
clinical examination using microcapillary pipette only for about 10mins to prevent traumatism. The 
collected GCF sample was stored at -70ºC.About 4ml blood was collected, centrifuged at 3000gm 
for 5min,serum was separated, transferred to plastic vial and stored at -70ºC. The samples were 
analyzed using ELISA.SNP-420 typing was done by DNA probes. Results after statistical analysis 
showed higher levels of resistin in both serum and GCF sample in all patients except the healthy 
subjects. GG genotype at-420 was significantly associated with periodontal inflammation and 
resistin level. This study concluded that resistin levels were higher in periodontitis and diabetes 
patients and SNP-420 is associated with periodontal inflammation and resistin levels. 
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Zimmermann et al. (2013)23 conducted a study to evaluate the circulating levels of 
adipokines in obese patients with and without periodontitis. A total of 78 patients were included in 
the study with 4 groups. Group 1 includes 20 normal weight patients without periodontitis, Group 2 
includes 20 normal weight patients with periodontitis, Group 3 includes 18 obese patients without 
periodontitis and Group 4 includes 20 obese patients with periodontitis. The clinical parameters like 
bleeding on probing, plaque index, probing depth and clinical attachment level were evaluated in all 
six sites. In addition to this anthropometric measurements like weight, height, waist and hip 
circumferences were measured to calculate BMI and waist-hip ratio to categorize into obese and 
normal weight patients.GCF sample was collected using paper strips and placed in microcentrifuge 
tube and stored at -80ºC. Fasted blood samples were collected, centrifuged, serum was separated by 
centrifugation and stored at -80ºC. The analysis was done using ELISA. The result shows higher 
levels of resistin in periodontitis group than in non periodontitis group. The group with obese 
patients showed higher TNF α levels. Serum IL-6 were highly correlated in patients who are obese 
with chronic periodontitis. The study concludes that resistin is present in both periodontitis and 
obese patients which favours proinflammation. 
Gokhale et al. (2014)2  evaluated  the levels of resistin in GCF of healthy, periodontitis and 
type 2 diabetes mellitus patients. A total of 60 patients were included in the study with 4 groups. 
Each group consists of 15 patients. Group 1 included  15 healthy patients with GI score ≤1 without 
loss of attachment, Group 2 includes systemically healthy chronic periodontitis patients with GI 
score≥1 and probing depth ≥5, Group 3 includes patients with type 2 diabetes mellitus with GI 
score ≤1 without any loss of attachment and with HbA1c ≥6.5%, Group 4 includes chronic 
periodontitis patients with type 2 diabetes mellitus with GI score ≥1,probing depth ≥5, HbA1c 
≥6.5%. The clinical parameters - plaque index, gingival index, probing depth were evaluated.GCF 
collection is done in tooth with greatest probing depth. Supragingival plaque is removed with 
curettes, air dried, isolated with cotton rolls and microcapillary pipette is placed at the entrance of 
Review of literature 
 
18 
 
the sulcus. About 4 microlitre of GCF is collected and stored at -20ºC. The evaluation of resistin 
from GCF is analysed by ELISA. The results showed highest levels of GCF in patients with chronic 
periodontitis with type 2 diabetes mellitus and lowest levels were found in healthy patients. From 
this study, it was concluded that GCF resistin levels were increased in chronic periodontitis patients 
with type 2 diabetes mellitus. Hence GCF resistin can be used as an inflammatory biomarker. 
Goncalves et al. (2015)24 conducted a study to evaluate the effects of non surgical 
periodontal therapy on  serum and GCF levels of adipokines in patients with chronic periodontitis 
with or without obesity. Study consists of 40 patients with two groups. Group1 involves 20 patients 
who were obese with periodontitis. Group 2 includes 20 patients who were non obese with 
periodontitis. The chronic periodontitis patients were grouped based on the clinical parameters like 
> 30% of teeth with probing depth and clinical attachment level ≥ 4mm and in atleast one site with 
probing depth and clinical attachment ≥5mm. Other parameters includes HbA1c <6.5%,FBS 70 to 
90 mg/dl and CRP<6mg/l. Anthropometric measurements like height, weight, waist and hip 
circumference were measured to calculate BMI and WHR calculation to categorise obese patients. 
Nonsurgical periodontal therapy (scaling and root planning was done within two weeks). GCF 
samples were collected from shallow and deep pockets using paper strips and stored at -80ºC. 
Fastened blood samples were collected, centrifuged and stored at -80ºC.Clinical parameters, GCF 
and blood samples were collected at baseline,3,6and 12 months post therapy analysis was done by 
ELISA. A total of 4 GCF samples and one serum sample were analysed for each patient. The results 
showed higher levels of resistin and TNF α  in shallow sites in obese patients than in  non obese at 6 
and 12 after therapy. IL 6 was higher in deep sites. Periodontal therapy yielded statistically 
improvement in clinical parameters. It was concluded that obesity has an influence on periodontal 
levels of adipokines independent of periodontal therapy and also SRP did not affect the levels of 
adipokines in all patients. 
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Kang S-K et al.  (2015)25 conducted an invitro study to  evaluate the effects of nicotine and 
LPS on expression of resistin and the effect of expressed resistin on inflammatory cytokines, ECM, 
MMPs in human periodontal ligament cells. LPS from Porphyromonas gingivalis and nicotine were 
collected. IGg was obtained from rabbit polyclonal antiserum. Interfering RNAs against resistin 
were purchased. PDLCs were obtained from premolar and cultured. Upon stimulation with 
inflammatory human promoters, human PBLCs produced proinflammatory cytokines and 
chemokines . After culturing they were treated with LPS for  24 hours. The cells were collected by 
centrifugation and pretreated with resistin inhibitor Iso, resistin specific si RNA. The final 
measurement was done using ELISA. The results showed upregulation of resistin mRNA 
expression and its production in PDLC. LPS and nicotine mediated the expression of TNF α, IL-1β, 
IL-6, IL-12 and MMPs. Pretreatment with resistin inhibitor blocked nicotine LPS induced activation 
of various factors. From this study it was concluded that inhibition of resistin has anti-inflammatory 
effect which decreased the levels of inhibitory cytokines thus preventing the ECM breakdown. 
Mittal et al. (2015)26 observed the correlation between periodontitis and rheumatoid 
arthritis by using GCF resistin as a potent inflammatory marker. The study includes 100 patients 
with 4 groups. Group A consists of healthy individuals with with PI and GI <1 without any probing 
depth ≥5mm. Group B includes systemically healthy chronic periodontitis patients with PI and GI 
>1, PD≥5mm with radiographic evidence of boneloss. Group C includes rheumatoid arthritis 
patients without chronic periodontitis. Group D includes patients with periodontitis and rheumatoid 
arthritis. GCF collection was done by micropipettes with deepest periodontal pockets -20ºC. Results 
showed that highest level of resistin was observed in patients with chronic periodontitis and 
rheumatoid arthritis and lowest level of resistin in healthy individuals. GCF resistin levels were also 
correlated with PI, GI and probing depth. From this study it was concluded that GCF resistin levels 
were increased in both chronic periodontitis patients and it can be used as a potent inflammatory 
biomarker. 
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Rao et al. (2016)27 determined the serum and salivary levels of resistin in obese patients 
with chronic periodontitis. The study includes 30 patients and were divided into 2 groups. Group I 
includes obese individuals with healthy gingiva and Group II includes obese individuals with 
chronic individuals. Inclusion criteria includes the presence of atleast 20 teeth and healthy gingiva 
with probing depth of ≤ 3mm and for periodontitis >30% with clinical attachment level of 
>3mm.Clinical parameters include gingival index, clinical attachment level, BMI and obesity. All 
the clinical measurements were determined. After this serum and saliva sample collection was done. 
Unstimulated whole saliva and blood samples were collected. Analysis was done using ELISA. 
Statistical analysis was done. The results showed highest resistin levels in serum and salivary 
sample of periodontitis patients. Correlation of serum resistin concentrations with salivary resistin 
concentration was positive among both the groups. A positive correlation was observed between 
resistin and clinical parameters which was statistically significant. From this study it was concluded 
that resistin can be considered as a potential biomarker for periodontal diseases and obesity. This 
was also found to play a role in inflammatory diseases. 
Suresh et al. (2016)28 correlated the GCF resistin levels in obese patients with and without 
periodontitis and also correlated the resistin levels with disease severity. The study includes a total 
of 90 patients with 4 groups. Group 1 includes 20 obese patients with generalised chronic 
periodontitis , Group 2 includes 25 obese patients with healthy periodontium, Group 3 includes 25 
non obese subjects with generalised chronic periodontitis and Group 4 includes 15 non obese 
subjects with healthy periodontium. Healthy patients were included based on GI score – 0 and 
generalised chronic periodontitis were included by clinical attachment level of 3-5mm at more than 
30% of sites. Other clinical parameters like plaque index and probing depth were also measured. 
Obese patients were categorized based on BMI >25kg/m2. GCF collection was done in multiple 
sites for healthy patients using micropipettes to get a volume of 2 microlitre and then stored at -
71ºC. Analysis was done using ELISA. This study concluded that GCF resistin levels were 
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significantly higher in obese patients with generalised chronic periodontitis than with non obese 
subjects with healthy periodontium. 
Longo et al. (2017)29 evaluated the interferences of GCF derived inflammatory markers 
from periodontitis patients on glycemic control and type 2 diabetes mellitus. A total of 21 subjects 
were included in the study among which 14 were diabetic and 7 were non diabetic patients with 
chronic periodontitis in all 21 subjects. The inclusion criteria showed probing depth and clinical 
attachment level in  ≥30% sites with ≥4mm  and bleeding on probing. Previously diagnosed 
diabetes mellitus before 3 years and under medication with HbA1c with  ≥8.0% and controlled 
diabetes as <8% and non diabetic subjects as <6%. Clinical parameters like plaque index, gingival 
index, probing depth and attachment level measured with UNC probe. GCF sample was collected 
using paper strips in all teeth with probing depth >6mm and stored at -80ºC.Analysis for cytokines 
was done by ELISA. The results showed high levels of inflammatory cytokines from the samples 
collected from deep periodontal pockets. There was no statistical difference between IL-6, IL-
8,TNF α according to the presence of diabetes and HbA1c levels. From this study it was concluded 
that inflammatory mediators in GCF are dependant to the local response and doesnot correlate with 
diabetic status. 
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MATERIALS AND METHODS 
PATIENT SELECTION: 
The study includes a total of 37 patients with 20 systemically healthy chronic periodontitis 
patients and 17 chronic periodontitis patients with type 2 diabetes mellitus.The patients were selected 
from the outpatient ward who visited the Department of Periodontology, KSR Institute of Dental 
Science and Research, Tiruchengode, Tamilnadu. The study protocol was analys ed and approved by 
the Institutional ethical committee and review board. Study protocol was explained to the patients 
and written informed consent was obtained before enrollement.  
SELECTION CRITERIA: 
INCLUSION CRITERIA: 
For Group I: (Systemically healthy Chronic periodontitis patients) 
 Systemically healthy individuals 
 GI Score > 1 
 Minimum of 3 teeth with PD ≥ 5 mm 
 RBS Level ≤ 120 mg/dl 
For Group II: (Chronic periodontitis patients with type 2 diabetes mellitus) 
 Patients with type 2 diabetes mellitus 
 GI Score > 1 
 Minimum of 3 teeth with PD ≥ 5 mm 
 RBS Level > 200 mg/dl 
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EXCLUSION CRITERIA: 
 Patients with systemic disorders. 
 Patients who received previous periodontal treatment. 
 Patients with antibiotic / anti-inflammatory drug regimen prior to the study. 
 Patients who are smokers or use of smokeless tobacco in any form. 
 Pregnant or lactating women.  
STUDY DESIGN: 
The study includes a total of 40 patients with two groups – 20 patients in each group.  
GROUP I : Systemically healthy chronic periodontitis patients 
GROUP II: Chronic periodontitis patients with type 2 diabetes mellitus 
The clinical parameters including plaque index (PlI), gingival index (GI), probing depth (PD) 
and clinical attachment level (CAL) were recorded for all the patients at baseline and at 3 months 
following non surgical periodontal therapy. GCF samples were collected from the tooth with deepest 
periodontal pocket at baseline and at 3 months following non surgical periodontal therapy. The levels 
of resistin in GCF samples were analysed using an Enzyme Linked Immunosorbent Assay. 
 
Armamentarium for invivo examination: 
1. Sterile surgical gloves 
2. Face mask 
3. Mouth mirror 
4. William’s calibrated periodontal probe 
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5. Explorer 
6. Stainless steel tray 
7. Cotton pliers 
8. Sterile cotton pellets and gauze 
Armamentarium for GCF collection 
1. Micro capillary pipette 
2. Pipette 
3. Plastic vials 
4. Phosphate buffer solution 
5. Thermocol box 
6. Dry ice. 
Armamentarium for nonsurgical periodontal treatment 
1. Ultrasonic scaler and tips 
2. Curettes 
3. Local anaesthetics ( 2% lignocaine with 1:80,000 adrenaline) 
Armamentarium for assay procedure 
1. ELISA kit 
2. ELISA reagent 
3. ELISA reader 
Clinical parameters:  
1. Plaque index- Loe’s modification (1967)30 
2. Gingival index- Loe’s modification (1967)30 
3. Probing pocket depth4 
4. Clinical attachment level4 
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PLAQUE INDEX (PlI)- LOE’S MODIFICATION (1967) 
The Plaque Index was described by Silness.J and Loe.Hin 1964 and modified by Loe.H in 
1967. The plaque was assessed after air drying the teeth on four sites namely mesiobuccal, 
midbuccal, distobuccal and lingual.30 
Instrument used: 
1.  Mouth mirror 
2. Dental explorer 
The tooth were air-dried and examined visually. When no plaque is visible, an explorer was used 
on the surface. The explorer was passed across the surface in the cervical third and near the entrance 
to the gingival sulcus. The following scores are given.30 
Scores for Plaque Index 
Score Criteria 
0 No plaque 
1 
A film of plaque adhering to the free gingival margin and adjacent area of the tooth. The 
plaque may be seen only by running a probe, across the tooth surface. 
2 
Moderate accumulation of soft deposits within the gingival pocket, on the gingival margin 
and/or adjacent tooth surface, which can be seen by the naked eye. 
3 
Abundance of soft matter within the gingival pocket and /or on the gingival margin and 
adjacent tooth surface. 
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Calculation of Plaque index: 
Plaque score for the area: 
 Each site (disto-facial, facial, mesio-facial, lingual) is assigned a score from 0 to 3 
Plaque score for a tooth: 
The scores from the four sites of the tooth are added and then divided by four. 
Plaque score for the individual: 
The indices for each of the teeth are added and then divided by the total number of teeth examined. 
The scores ranged from 0 – 3.30 
Interpretation: 
Excellent 0 
Good 0.1 – 0.9 
Fair 1.0 – 1.9 
Poor 2.0 – 3.0 
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GINGIVAL INDEX – LOE’S MODIFICATION (1967) 
The Gingival Index (GI) was developed by Loe.H and Silness.J in 1963, solely for the 
purpose of assessing the severity of gingivitis and its location in four possible areas by examining 
only the qualitative changes (i.e., severity of the lesion) of the gingival soft tissue. In 1967, Loe.H 
detailed the sequence of examination to include entire teeth instead of six teeth.30 
Instruments used: 
1. Mouth mirror  
2. Periodontal probe. 
The tissues surrounding each tooth were divided into four gingival scoring units: distofacial 
papilla, facial margin, mesio-facial papilla and the entire lingual gingival margin. The teeth and 
gingiva should be dried lightly with a blast of air and /or cotton rolls. Each of the 4 gingival units 
were assessed and following scores were given.30 
Gingival index score 
Score Criteria 
0 Absence of inflammation/normal gingiva. 
1 Mild inflammation, slight change in color, slight edema; no bleeding on probing. 
2 Moderate inflammation; moderate glazing, redness, edema and hypertrophy, 
bleeding on probing. 
3 Severe inflammation; marked redness and hypertrophy, ulceration, tendency to 
spontaneous bleeding. 
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Calculation of Gingival Index: 
Gingival Index Score for the site:  
Each site (disto-facial, facial, mesio-facial, lingual) is assigned a score from 0 to 3.  
Gingival Index Score for a tooth: 
 The scores from the four areas of the tooth are added and then divided by four.  
Gingival Index for the individual: 
The indices for each of the teeth are added and then divided by the total number of teeth examined. 
The scores ranged from 0 – 3.30 
Interpretation: 
Gingival scores Condition 
0.1 – 1.0 Mild Gingivitis 
1.1 – 2.0 Moderate Gingivitis 
2.1 – 3.0 Severe Gingivitis 
 
PROBING POCKET DEPTH (PPD) AND CLINICAL ATTACHMENT LEVEL (CAL): 
Probing pocket depth was measured as the distance between free gingival margin and the base 
of the pocket and clinical attachment level was measured as the distance between the cemento enamel 
junction and the base of the pocket.4 
GCF COLLECTION: 
GCF samples were collected from all patients from the tooth with deepest periodontal pockets 
at baseline at 3 months following nonsurgical periodontal treatment.The selected tooth was dried 
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using a three- way air syringe. After supragingival plaque was removed using sterile curets, the sites 
were isolated using cotton rolls to prevent contamination with saliva. GCF collection was done using 
a calibrated volumetric microcapillary pipette which has markings from 1μl to 5μl. A volume of 4μl  
of GCF was collected by gently placing the sterile microcapillary pippette at the entrance of the 
gingival sulcus.GCF collection can be done for 10 – 15 minutes.2,31 If GCF was not collected in 
allotted time, the site and GCF can be discarded. This was done to prevent  trauma to gingiva. 
Microcapillary pipettes contaminated with blood were discarded. The collected GCF was then 
transferred to eppendorf tube and the sample was diluted in Phosphate Buffer Saline (PBS) to make a 
total volume of 120μl.These air tight eppendorf tubes were placed immediately in thermocol box 
containing dry ice as atransporting medium and stored at-80˚C. 
 
NON-SURGICAL PERIODONTAL THERAPY: 
All the patients received non-surgical periodontal therapy, which included intensive oral 
hygiene phase, full-mouth scaling and root planing, maintenance and monitoring of oral hygiene. 
During the first visit (at baseline) complete scaling using ultrasonic scaler was performed and root 
planing was performed using curettes until a smooth, hard and calculus-free root surface was 
achieved. Oral hygiene instructions were given to all the subjects. Clinical parameters were recorded 
and GCF samples are obtained at baseline (prior to SRP) and 3 months following the therapy. 
 
ASSAY PROCEDURE: 
The Resistin levels in the collected GCF samples were measured using Enzyme Linked 
Immunosorbent Assay (ELISA). The assay employed the quantitative sandwich ELISA technique. 
ELISA is one of the immunoassay method using antibodies to capture an antigen and an enzyme 
labelled antibody to estimate the amount of antigen. The desired antigen is captured by one antibody 
and bound to the plate. A second antibody binds the immobilized antigen for detection and 
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quantification. The antigen must contain at least two non-overlapping epitope sites capable of 
binding different antibodies. 
 Human Resistin ELISA kit from Bioassay technology laboratory was used for the  assay. The 
assay procedure was done based on the manufacturers instruction. 
INSTRUMENTS AND MATERIALS USED TO ASSESS RESISTIN IN GCF: 
1 Standard(6400ng/L)  0.5ml  
2 Standard diluent 3ml  
3 MicroELISA Stripplate 12w×8s  
4 Str- HRP-Conjugate Reagent 6ml  
5 30×wash solution 20ml 
6 Biotin-RESISTIN Ab 1ml  
7 Chromogen Solution A 6ml 
8 Chromogen Solution B 6ml 
9 Stop Solution 6ml 
10 Closure plate membrane 2 
11 Sealed bag 1 
12 37℃ incubator  
13 Standard Enzyme reader. 
14 Precision pipettes and Disposable pipette tips  
15 Distilled water 
16 Disposable tubes for sample dilution 
17 Absorbent paper 
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TEST PRINCIPLE: 
The kit uses a double-antibody sandwich enzyme-linked immunosorbentassay (ELISA) to 
assay the level of Human Resistin（RESISTIN）in samples. Add Resistin（RESISTIN） to 
monoclonal antibody enzyme well which is pre-coated with Human 
Resistin（RESISTIN）monoclonal antibody, incubated and then add Resistin（RESISTIN) 
antibodies labeled with biotin, and combined with Streptavidin-HRP to form immune complex; then 
carry out incubation and washing again to remove the uncombined enzyme. Then add Chromogen 
Solution A, B, the color of the liquid changes into the blue, And at the effect of acid, the color finally 
becomes yellow. The chroma of color and the concentration of the Human substance 
Resistin（RESISTIN）of sample were positively correlated. 
 
STANDARD PREPARATION:  
Five clear test tubes were numbered from S1 to S5. 
STANDARD NO 5 : Pipette 120 µl of original standard reagent and transfer to test tube 
S5.Add 120 µl of standard diluents. 
STANDARD NO 4: Pipette 120 µl of standard No 5 and transfer to tube S4.Add 120 µl of 
standard diluents. 
STANDARD NO 3: Pipette 120 µl of standard No 4 and transfer to tube S3.Add 120 µl of 
standard diluents 
STANDARD NO 2: Pipette 120 µl of standard No 3 and transfer to tube S2.Add 120 µl of 
standard diluents 
STANDARD NO 1: Pipette 120 µl of standard No 2 and transfer to tube S1.Add 120 µl of 
standard diluents 
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ASSAY PROCEDURE: 
1. Duplication of blank,standard and sample were done. 
2. Blank 1: Blank 1 is prepared by adding chromogen A 50 µl, chromogen B 50 µl, stop 
solution 50 µl and distilled water 100 µl. 
3. Blank 2: Blank 2 is prepared by adding chromogen A 50 µl, chromogen B 50 µl, stop 
solution 50 µl , streptavidin HRP 50 µl and distilled water 50µl. 
4. Sample: About 40 µl of sample is taken to which 10 µl of resistin antibody and 50 µl of 
streptavidin 50 µl is added. It is sealed with membrane and is gently shaked. Incubation is 
done for 60 minutes at 37ºC. 
5. 30x washing concentrate is diluted 30 times with distilled water and is used for manual 
washing. 
6. Washing: After incubation, remove the membrane carefully.The remaining liquid in enzyme 
plates are removed.0.35ml of washing solution is added and marinated for 1-2 minutes. The 
excess liquid is drained. The process was repeated 5 times. 
7. Add 50 µl of Chromogen A and 50 µl of Chromogen B to  the sample. 
8. Incubation is done at 37ºC for 10 minutes. 
FIGURE 4:SAMPLE DILUTION 
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9. After 10 minutes 50µl of stop solution was added to stop the reaction.(colour changes from 
blue to yellow colour) 
10. The plate is read at wavelength of 450nm using ELISA reader. The absorbance was checked 
periodically. 
CALCULATION OF RESULTS: 
 The standard curve was plotted on X-Y graph paper, with standard concentration on the x-
axis and absorbance on y-axis. The best- fit straight line was drawn through the standard points. 
Resistin concentrations were assessed by comparing the average sample optical density readings to 
the concentrations from the assay standard curve. 
 
                                                     CHART 1: X-Y GRAPH 
                                     
SENSITIVITY: 
 The minimum detectable dose of Human Resistin was determined to be 10.21ng/L. Minimum 
detectable dose is defined as the analyte concentration resulting in an absorbance that is 2 standard 
deviations higher than that of the blank (diluents buffer). 
SPECIFICITY: 
 This ELISA antibody pair detects Human Resistin. Other species were not determine 
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C. Armamentarium for non 
surgical periodontal therapy 
B. Armamentarium for GCF collection A. Armamentarium for clinical examination 
FIGURE 5 : ARMAMENTARIUM 
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C. Measuring probing depth 
FIGURE 6 : PRE-OPERATIVE PHOTOS OF CHRONIC PERIODONTITIS 
PATIENT 
A. Front view 
 
B. Lateral view 
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D. Storing the sample in dry ice  C. Transferring GCF sample into 
eppendorf tube 
E. Deep freezer for storage of samples 
FIGURE 7: GCF COLLECTION 
A. Transferring PBS into eppendorf tube B.GCF collection using microcapillary pipette 
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B. Root planing done using curettes 
FIGURE 9 :POST OPERATIVE PHOTO 
A. Scaling using ultrasonic scalers 
FIGURE 8: NON SURGICAL PERIODONTAL THERAPY 
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FIGURE 10 : ELISA PLATE WITH 96 WELLS 
FIGURE 11 : ELISA REAGENTS 
FIGURE 12: GCF SAMPLE FOR ASSAY 
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FIGURE 13 : STANDARD PREPARATION 
FIGURE 14  : ELISA PROCESSING 
FIGURE 15 : AFTER ADDING CHROMOGEN 
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FIGURE 16: ADDING STOP SOLUTION 
FIGURE 17: ELISA READER 
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Data were analyzed using the statistical software SPSS 16 (SPSS, Chicago, IL, USA). 
Shapiro wilks test was used to assess normality of the obtained data. Descriptive statistics was 
obtained. Based on distribution of data comparisons between the study groups, the analysis 
was performed using the Mann whitney U test (non normal distribution). Wilcoxon signed 
rank test (Intragroup analyses) was performed to identify the changes in clinical parameters 
before and after treatment in study groups. P <0.05 was accepted as statistically significant. 
 
P VALUE: 
The P value or calculated probability is the estimated probability of rejecting the null 
hypothesis of a study question when that hypothesis is true. Differences between the two 
populations were considered significant when p < 0.05. 
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Table No 1, Chart 2 and Chart 3 show the comparison of clinical parameters before 
and after non surgical periodontal therapy in Group I- Chronic periodontitis patients. 
Wilcoxon signed rank test was used. The mean value for plaque index before and after non 
surgical periodontal therapy are 1.78 and 1.02 respectively. The significant p-value of this 
wilcoxon signed rank test infers that plaque level was reduced after therapy. The mean for 
gingival index before and after non surgical periodontal therapy are 2.1 and 1.46 respectively. 
The significant p-value infers that gingival inflammation was reduced after non surgical 
periodontal therapy. The mean value for probing depth before and after non surgical 
periodontal therapy are 3.19 and 2.55 respectively. The mean value for clinical attachment 
level before and after non surgical periodontal therapy are 3.21 and 1.87 respectively. Both 
the clinical parameters has significant p-value. This infers that non surgical periodontal 
therapy has reduced the probing depth and improved clinical attachment level. 
  Table No 2,Chart 4,Chart 5 show the comparison of clinical parameters before and 
after non surgical periodontal therapy in Group II- Chronic  periodontitis patients with type 2 
diabetes mellitus. Wilcoxon signed rank test was used. The mean value for plaque index 
before and after non surgical periodontal therapy are 1.97 and 1.06 respectively. The 
significant p-value of this wilcoxon signed rank test infers that plaque accumulation was 
reduced after therapy. The mean for gingival index before and after non surgical periodontal 
therapy are 2.34 and 1.61 respectively. The significant p-value infers that gingival 
inflammation was reduced after non surgical periodontal therapy. The mean value for probing 
depth  before and after non surgical periodontal therapy are 3.18 and 2.66 respectively. The 
mean value for clinical attachment level before and after non surgical periodontal therapy are 
3.23 and 2.15 respectively. Both the clinical parameters has significant p-value. This infers 
that non surgical periodontal therapy has reduced the probing depth and improved clinical 
attachment level. 
Results 
 
43 
 
Table 3 and Chart 6 show the comparison of  baseline and post operative resistin 
level  in Group I- Chronic periodontitis patients. Wilcoxon signed rank test was used. The 
significant p-value infers that non surgical periodontal therapy has reduced the levels of 
resistin comparing to it baseline level in  chronic periodontitis patients. 
Table 4 and Chart 7 show the comparison of  baseline and post operative resistin 
level  in Group II- Chronic periodontitis patients with type 2 diabetes mellitus. Wilcoxon 
signed rank test was used. The significant p-value infers that non surgical periodontal therapy 
has reduced the levels of resistin comparing to it baseline level in  chronic periodontitis 
patients with type 2 diabetes mellitus. 
Table 5, Chart 8 show the comparison of resistin level at baseline between two 
groups, Group I - Chronic  periodontitis patients and Group II - Chronic periodontitis patients 
with type 2 diabetes mellitus. Mann Whitney U test was used. The mean values of resistin 
level for two groups at baseline are 62.44 and 59.09.The insignificant p-value infers that there 
is no statistical difference in resistin levels at baseline between two groups.  
Table 6, Chart 9 show the comparison of resistin level after SRP between two 
groups, Group I - Chronic periodontitis patients and Group II - Chronic periodontitis patients 
with type 2 diabetes mellitus. Mann Whitney U test was used. The mean values of resistin 
level for two groups after SRP are 62.44 and 59.09.The insignificant p-value infers that there 
is no statistical difference in resistin levels after SRP between two groups. 
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TABLE NO 1: Comparison of clinical parameters before and after non surgical  
periodontal therapy (SRP) in Group I - Chronic periodontitis patients 
 
Clinical parameters 
Chronic periodontitis patients 
 
 
N 
 
 
Mean 
 
 
SD 
Wilcoxon 
signed 
rank test 
p value 
 
Plaque index at baseline 
 
 
20 
 
1.78 
 
0.561 
 
 
0.001* 
 
Plaque index after SRP 
 
 
20 
 
1.02 
 
0.426 
 
Gingival index at baseline 
 
 
20 
 
2.1 
 
0.354 
 
 
0.001* 
 
Gingival index after SRP 
 
 
20 
 
1.46 
 
0.37 
 
Probing depth at baseline 
 
 
20 
 
3.19 
 
0.373 
 
 
0.001* 
 
Probing depth after SRP 
 
 
20 
 
2.55 
 
0.349 
 
Clinical attachment level at baseline 
 
 
20 
 
3.21 
 
0.711 
 
 
0.001* 
 
Clinical attachment level after SRP 
 
 
20 
 
1.87 
 
0.356 
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Chart 2: Comparison of  Plaque Index and Gingival Index  before and after 
SRP in Group I - Chronic periodontitis patients 
               
 
Chart 3: Comparison of  Probing depth and Clinical attachment level before and 
after SRP  in Group I -  Chronic periodontitis patients 
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Table no 2: Comparison of clinical parameters before and after non surgical periodontal 
therapy (SRP) in Group I1- Chronic periodontitis patients with type 2 diabetes mellitus 
 
 
 
 
 
 
 
 
Clinical parameters 
Group 2- Chronic periodontitis patients 
with type 2 diabetes mellitus 
 
 
 
N 
 
 
 
Mean 
 
 
 
SD 
Wilcoxon 
signed rank 
test 
p value 
 
Plaque index at baseline 
 
17 
 
1.97 
 
0.58 
 
 
0.001*  
Plaque index after SRP 
 
17 
 
1.06 
 
0.28 
 
Gingival index at baseline 
 
17 
 
2.34 
 
0.379 
 
 
0.001*  
Gingival index after SRP 
 
17 
 
1.61 
 
0.291 
 
Probing depth at baseline 
 
17 
 
3.18 
 
0.41 
 
 
0.002*  
Probing depth after SRP 
 
17 
 
2.66 
 
0.241 
 
Clinical attachment level at baseline 
 
17 
 
3.23 
 
0.663 
 
 
0.001*  
Clinical attachment level after SRP 
 
17 
 
2.15 
 
0.38 
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CHART 4: Comparison of  Plaque index and Gingival index before and after 
SRP in Group II - Chronic periodontitis patients with type 2 diabetes mellitus 
 
                  
 
CHART 5: Comparison of Probing depth and Clinical attachment level before and after 
SRP in Group II - Chronic periodontitis patients with type 2 diabetes mellitus  
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Table 3: Comparison of  baseline and post operative resistin level  in 
Group 1-Chronic periodontitis patients 
 
 
CHART 6: Comparison of  baseline and post operative resistin level  in 
Group 1-Chronic Periodontitis patients 
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Resistin at
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SRP
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44.43
  
 
RESISTIN LEVEL 
 
 
 
N 
 
 
 
Mean 
 
 
 
SD 
Wilcoxon 
signed 
rank test 
p value 
 
Resistin level at baseline in Chronic 
periodontitis patients 
 
20 
 
62.44 
 
11.577 
 
 
 
0.001*  
Resistin level after SRP in Chronic 
periodontitis patients 
 
20 
 
44.43 
 
13.754 
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Table 4: Comparison of  baseline and post operative resistin level  in 
Group I1-Chronic periodontitis patients with type 2  diabetes mellitus 
 
 
CHART 7: Comparison of  baseline and post operative resistin level  in 
Group II-Chronic periodontitis patients with type 2 diabetes mellitus 
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RESISTIN LEVEL 
 
 
 
N 
 
 
 
Mean 
 
 
 
SD 
Wilcoxon 
signed rank 
test 
p value 
 
Resistin level at baseline in Chronic 
periodontitispatients with type 2 diabetes 
mellitus 
 
17 
 
59.09 
 
7.062 
 
 
0.001* 
 
Resistin level after SRP in Chronic 
periodontitis patients with type 2 diabetes 
mellitus 
 
17 
 
42.36 
 
7.057 
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TABLE NO 5: Comparison of resistin level at baseline between two groups. Group I - 
Chronic periodontitis patients and Group II - Chronic periodontitis patients with type 2 
diabetes mellitus 
 
CHART 8: Comparison of resistin level at baseline between two groups. Group I - 
Chronic periodontitis patients and Group II - Chronic periodontitis patients with type 2 
diabetes mellitus 
           
57
58
59
60
61
62
63
Chronic periodontitis Chronic periodontitis
with type 2 diabetes
mellitus
62.44
59.09
BASELINE LEVELS OF RESISTIN
 
 
RESISTIN LEVEL 
 
 
N 
 
 
Mea
n 
 
 
SD 
 
 
Std. 
Error 
Mean 
Mann 
whitney U 
test 
P value 
 
RESISTIN at 
Baseline 
 
Chronic periodontitis patients 
 
20 
 
62.44 
 
11.577 
 
2.589 
 
 
0.201  
Chronic periodontitis patients 
with type 2 diabetes mellitus  
 
17 
 
59.09 
 
7.062 
 
1.713 
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TABLE NO 6: Comparison of resistin level after SRP between two groups. Group I - 
Chronic periodontitis patients  and Group II - Chronic periodontitis patients  with type 2 
diabetes mellitus 
 
CHART 9: Comparison of resistin level after SRP between two groups. Group I - 
Chronic periodontitis patients and Group II - Chronic periodontitis patients with type 2 
diabetes mellitus 
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RESISTIN LEVEL 
 
 
N 
 
 
Mean 
 
 
SD 
 
 
Std. 
Error 
Mean 
Mann 
whitney U 
test 
P value 
 
RESISTIN 
after SRP 
 
Chronic periodontitis patients 
 
20 
 
44.43 
 
13.754 
 
3.075 
 
 
0.063  
Chronic periodontitis patients 
with  type 2 diabetes mellitus 
 
17 
 
42.36 
 
7.057 
 
1.712 
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Chronic periodontitis is a result of chronic inflammatory response to the accumulated 
microbial plaque and calculus on the tooth surface. Toxic substances produce by microbes 
initiate the release of inflammatory mediators which results in host mediated destruction of 
periodontal tissue.4The presence of periodontal pathogens and the host response to 
pathogenic bacteria creates a complex bi-directional series of host-microbial interaction. As a 
result of this, cascade of events takes place. 
During this cascade of events, various pro inflammatory cytokines and large 
quantities of destructive enzymes such as matrix metalloproteinase and inflammatory 
mediators are produced resulting in more extracellular degradation, osteoclast activation and 
differentiation, leading to further collagen and bone destruction ultimately ending up in more 
tissue destruction. Although the immune/inflammatory processes are essential for protecting 
the host against infection, the exaggerated host response to pathogenic bacteria results in 
periodontal tissue destruction.5 
These inflammatory mediators also act as a biomarker for the periodontal disease. 
There are numerous biomarkers for periodontal disease, one such biomarker is the newly 
discovered Resistin. These are adipokines which are cysteine rich proteins, expressed in very 
low level in adipocytes and higher level in circulating monocytes, macrophages, lymphocytes 
and mononuclear leukocytes. These resistin are mainly involved in obesity and diabetes 
mellitus. Later, it was found to be involved in chronic periodontitis and various inflammatory 
conditions like rheumatoid arthritis, retinopathy, chronic kidney diseases, atherosclerosis, 
coronary artery diseases.1,2,5 
Various immune cells like monocytes, macrophages, lymphocytes and mononuclear 
leukocytes act as a source for resistin in which mononuclear leucocytes (neutrophils) act as a 
major source of resistin. It acts as a proinflammatory molecule and stimulates the synthesis 
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and secretion of TNF-α and IL-12. Inturn these TNF-α, IL-6 and IL-1β  increases the resistin 
expression in PBMCs, thus inducing its own production in a positive feedback cycle.2 
Lipopolysaccharides produced by periodontal pathogens also stimulates neutrophils and 
hence increased amount of resistin is released as an inflammatory exudate from GCF of 
inflamed periodontal tissues.12 
Periodontitis being a sixth complication of diabetes, a bidirectional relationship has 
been established between diabetes and periodontitis. The interrelationship between diabetes 
mellitus and periodontitis has been studied for many years. At present there is strong 
evidence to suggest that the incidence and severity of periodontitis is influenced by the 
presence or absence of diabetes mellitus, as well as the degree to which the disease is 
controlled by patients.32 As resistin levels are increased in periodontitis with chronic 
subclinical inflammation, the level of resistin increases in circulation and acts on GLUT. 
Thus it increases the insulin resistance by decreasing insulin sensitivity leading to increased 
risk for type II diabetes mellitus. Hence resistin could be one of the ideal biomarker which 
provides link among Resistin-Periodontitis-Diabetes mellitus triad.1 
The aim of this study is to evaluate the levels of Resistin in gingival crevicular fluid 
before and after non surgical periodontal therapy in systemically healthy chronic periodontitis 
patients and in chronic periodontitis patients with Type 2 Diabetes mellitus. A total of 39 
patients were included in the study and were divided into 2 groups – Group I (20 patients) : 
Chronic periodontitis patients and Group II (17 patients) : Chronic periodontitis with type II 
diabetes mellitus patients. There were 2 dropouts in Group II. So a total of 37 patients 
completed the study.  
   Clinical parameters like plaque index, gingival index, probing depth and clinical 
attachment level were measured at baseline and 3 months following non surgical periodontal 
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therapy. Plaque index helps in assessing the oral hygiene of the patients and gingival index 
aids in assessing the severity of gingival inflammation before and after SRP.30 Patients with 
poor oral hygiene and severe gingival inflammation at 3 months after SRP were excluded 
from the study.  Probing pocket depth and clinical attachment level were measured, as these 
are most important clinical parameters to evaluate the amount of clinical attachment loss or 
gain after SRP in chronic periodontitis patients. Hence probing depth ≥5mm was considered 
as defining criteria for chronic periodontitis.2Though bleeding on probing is the most 
important clinical sign which reflects the level of periodontal inflammation, it was not 
evaluated. And also the periodontal probe which was used is not pressure-calibrated to 
standardize probing forces. 
In the present  study, a period of 3 months has been chosen for re-evaluation after non 
surgical periodontal therapy for the assessment of both clinical parameters and levels of 
resistin. This is because, the appropriate time interval required for evaluating the effect of 
nonsurgical periodontal therapy which aids in complete resolution of gingival inflammation 
and tissue repair is approximately 3 months.33 This resolution of the inflammation inturn 
reduces the level of resistin and hence biochemical analysis was also done after a period of 3 
months following SRP. 
 GCF is an important diagnostic aid containing host cell products (cytokines, 
antibody, enzymes), products of tissue destruction, plasma derived molecules and subgingival 
microbial products.2,14 Hiroshima et al (2012)12 evaluated the levels of resistin in GCF, serum 
and synovial fluid and found mean resistin concentration in GCF was remarkably higher than 
serum and synovial fluid. As GCF concentration of resistin was higher than blood, GCF was 
chosen as a diagnostic aid for resistin. GCF derived biomarkers combined with clinical 
measures provide a greater specificity to identify the status of periodontal tissues and 
response to therapy. There are no previous studies in accordance with the present study. This 
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is the first study to evaluate the resistin levels in GCF of chronic periodontitis patients with 
and without type II diabetes mellitus before and after non surgical periodontal therapy.  
  There are few cross sectional studies which evaluated the levels of resistin in GCF of 
chronic periodontitis patients. These includes studies by Gokhale et al (2014)2, Hiroshima et 
al (2012)12, Suresh et al (2016)28, Longo et al (2017)29, and Mittal et al (2015)26. Serum levels 
of resistin was evaluated by Zimmerman et al (2013)23, Rao et al (2016)27 and Devanoorkar et 
al(2012)21. A study done by Devanoorkar et al (2012)21 assessed the effectiveness of non 
surgical periodontal therapy on serum resistin levels and clinical parameters after SRP in 
chronic periodontitis patients. 
The results of the study comparing the clinical parameters of both the groups, 3 
months following non surgical periodontal therapy showed a statistical significant 
improvement. The positive clinical outcomes like reduction in probing depth and 
improvement in clinical attachment level obtained in both the groups are in agreement with 
the previously reported findings of Badersten et al (1987)34 and  Weijden et al (2002)35 on the 
clinical efficacy of SRP in the treatment of chronic periodontitis. This study is another 
testament for the importance of nonsurgical periodontal therapy by means of SRP. 
  The results also showed statistically significant reduction in resistin levels in both the 
groups after non surgical periodontal therapy. As SRP reduces the subgingival load of 
periodontopathogens  responsible for periodontal inflammation and tissue breakdown, there 
is reduction in inflammation. This in turn reduces the proinflammatory cytokines, which 
infers reduction in resistin level after SRP. This is the first study to evaluate the GCF resistin 
levels in chronic periodontitis patients after SRP. Similar to the present study, Devanoorkar et 
al (2012)21 evaluated the resistin levels in chronic periodontitis patients after non surgical 
periodontal therapy (SRP). But he analysed in serum and obtained a negative correlation of 
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serum resistin levels after non surgical periodontal therapy. As mentioned previously, study 
by Hiroshima et al (2012)12 showed concentration of resistin in GCF is higher than serum and 
hence GCF was used as a diagnostic aid in the present study which showed statistically 
significant levels of resistin after SRP. 
On intergroup comparison of resistin levels at baseline and also after SRP, there is no 
significant difference in GCF resistin levels in chronic periodontitis patients and in chronic 
periodontitis patients with type 2 diabetes mellitus. There is no correlation of resistin levels at 
baseline which is in accordance with the study by Hiroshima et al (2012)12, in which he 
concluded that there is no statistical difference in GCF resistin levels in chronic periodontitis 
and chronic periodontitis patients with type 2 diabetes mellitus. Contrary to our result, a cross 
sectional study by Gokhale et al (2014)2 reported that GCF resistin levels were higher in 
chronic periodontitis patients with type 2 diabetes mellitus than in systemically healthy 
chronic periodontitis patients.  
Certain limitations of the study pertaining to this result should be noted. Healthy 
group was not included in the study which fails to compare and correlate the clinical 
parameters with  the resistin level in healthy and disease conditions. And also blood glucose 
level was not evaluated after 3 months following non surgical periodontal therapy. The 
reduced blood glucose level systemically may also reduce the resistin level which can also be 
the reason for insignificant resistin levels between two groups after non surgical periodontal 
therapy. 
In brief, the limitations of the study are, healthy group was not included, blood 
glucose levels were not evaluated 3 months after SRP and pressure sensitive probe was not 
used to standardise the probing force. 
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 Further clinical trials have to be done with proper study design and protocols, to 
determine the efficacy of non surgical periodontal therapy on resistin levels and periodontal 
disease condition. 
Summary and conclusion 
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Following conclusions were elucidated from the results of the present study 
 Non surgical periodontal therapy – SRP is found to be effective in the treatment of 
chronic periodontitis patients with and without diabetes mellitus. 
 The elevated levels of GCF resistin reflect the severity of periodontal disease. 
 GCF resistin can be a useful biomarker to detect the periodontal disease condition. 
 
            Based on the results obtained from the present study, we summarise that GCF resistin 
is one of the novel biomarkers for periodontal disease and is also related to periodontal 
disease severity. Both the clinical parameters and resistin levels have significantly improved 
after non surgical periodontal therapy. Thus nonsurgical periodontal therapy may be regarded 
as an effective treatment approach for chronic periodontitis patients with and without diabetes 
mellitus. 
Considering the limitations of the study, further studies on GCF resistin are needed 
with proper study protocols to draw more conclusive results. 
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ANNEXURE 1 
INFORMATION SHEET 
 
We are conducting a study on “EFFECT OF NON SURGICAL 
PERIODONTAL THERAPY ON  LEVELS OF RESISTIN IN GCF OF PATIENTS 
WITH CHRONIC PERIODONTITIS AND IN CHRONIC PERIODONTITIS 
PATIENTS WITH TYPE 2 DIABETES MELLITUS”. 
The identity of the patients participating in the research will be kept 
confidentialthroughout the study. In the event of any publication or presentation resulting 
from the research, no personally identifiable information will be shared.  
Taking part in the study is voluntary. You are free to decide whether to participate 
in the study or to withdraw at any time; your decision will not result in any loss of 
benefits to which you are otherwise entitled. 
The results of the special study may be intimated to you at the end of the study 
period or during the study if anything is found abnormal which may aid in the 
management or treatment. 
 
 
Name of the patient Signature / Thumb impression 
 
Name of the investigator Signature 
 
Date 
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ANNEXURE 2 
INFORMED CONSENT FORM 
 
EFFECT OF NON SURGICAL PERIODONTAL THERAPY ON  LEVELS OF 
RESISTIN IN GCF OF PATIENTS WITH CHRONIC PERIODONTITIS AND IN 
CHRONIC PERIODONTITIS PATIENTS WITH TYPE 2 DIABETES MELLITUS 
 
Name:                   Age/Sex                               Op.No:                                Date: 
Address: 
I, _________________ aged ____________ have been informed about my role in the study. 
1. I agree to give my personal details like name, age, sex, address, previous dental history & the 
details required for the study to the best of my knowledge. 
2. I will co-operate with the dentist for my intra oral examination & extra oral examination. 
3. I will follow the instructions given to me by the doctor during study. 
4. I  permit the dentist to take photos & I accept to undergo the procedures that are required for 
the study. 
5. If unable to participate in the study for reasons unknown, I can withdraw from the study. 
In my full consciousness & presence of mind, after understanding all the procedures in my own 
language, I am willing & give my consent to participate in this study. 
 
 
Name of the patient:                                                                      Name of the investigator: 
 
 
Signature/Thumb impression                                                        Signature 
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ANNEXURE 3 
EFFECT OF NON SURGICAL PERIODONTAL THERAPY ON LEVELS OF 
RESISTIN IN GCF OF PATIENTS WITH CHRONIC PERIODONTITIS AND IN 
CHRONIC PERIODONTITIS PATIENTS WITH TYPE 2 DIABETES MELLITUS 
                                                         PROFORMA 
                                                                      S.No: 
Name:                                                                                                           O.P.No: 
Age/Gender:                  Date: 
Occupation:  
Address and contact no: 
 
Chief complaints: 
 
Medical history: 
 
Dental history: 
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Personal history : 
 
 
Family history: 
 
 
Oral hygiene measures : 
 
 
Laboratory investigations : 
 
Blood sugar level (RBS) 
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CLINICAL PARAMETERS AT BASELINE 
 
PLAQUE INDEX – MODIFIED BY LOE (1967) 
 
18        17       16       15       14       13       12       11       21        22       23      24        25      26        27        28 
 
 
               
                
48        47         46      45       44       43       42         41      31       32       33       34      35       36       37    38 
 
PI score= 
 
GINGIVAL INDEX – MODIFIED BY LOE in 1967 
 
18        17       16       15       14       13       12       11       21        22       23      24        25      26        27        28 
 
 
               
                
48        47         46      45       44       43       42         41      31       32       33       34      35       36       37    38 
 
GI score= 
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PROBING POCKET DEPTH (in mm) 
18    17      16      15      14      13      12     11    21    22       23     24    25     26    27   28 
 
     48       47       46      45      44      43       42       41     31      32       33       34       35      36       37      38 
 
CLINICAL ATTACHMENT LEVEL (in mm) 
 
18    17      16      15      14      13      12     11    21      22       23     24       25      26       27      28 
 
     48       47       46      45      44      43       42       41     31      32       33       34       35      36       37      38 
GCF SAMPLE COLLECTION: 
 
 
TOOTH NUMBER 
 
RESISTIN 
  
 
 
 
 
 
                                                                                            SIGNATURE OF THE GUIDE 
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CLINICAL PARAMETERS AT 3 MONTHS (After SRP) 
 
PLAQUE INDEX – MODIFIED BY LOE (1967) 
18        17       16       15       14       13       12       11       21        22       23      24        25      26        27        28 
 
 
               
                
48        47         46      45       44       43       42         41      31       32       33       34      35       36       37    38 
 
PI score= 
 
GINGIVAL INDEX – MODIFIED BY LOE in 1967 
 
18        17       16       15       14       13       12       11       21        22       23      24        25      26        27        28 
 
 
               
                
48        47         46      45       44       43       42         41      31       32       33       34      35       36       37    38 
 
 
GI score= 
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PROBING POCKET DEPTH (in mm) 
18    17      16      15      14      13      12     11    21      22       23     24       25      26       27      28 
 
     48       47       46      45      44      43       42       41     31      32       33       34       35      36       37      38 
 
CLINICAL ATTACHMENT LEVEL (in mm) 
 
18    17      16      15      14      13      12     11    21      22       23     24       25      26       27      28 
 
     48       47       46      45      44      43       42       41     31      32       33       34       35      36       37      38 
 
GCF SAMPLE COLLECTION: 
 
 
TOOTH NUMBER 
 
RESISTIN 
  
 
 
 
 
                                                                                             SIGNATURE OF THE GUIDE 
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